Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620001047987
Ethics application status
Approved
Date submitted
16/09/2020
Date registered
15/10/2020
Date last updated
24/02/2022
Date data sharing statement initially provided
15/10/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Influence of Exercise Training on Chemoreflex Sensitivity in healthy adult humans.
Scientific title
Influence of aerobic or resistance exercise training compared with sedentary lifestyle on central and peripheral chemoreflexes in healthy adult humans.
Secondary ID [1] 302294 0
Nil known
Universal Trial Number (UTN)
U1111-1254-8318
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiovascular disease 319039 0
Condition category
Condition code
Cardiovascular 316995 316995 0 0
Coronary heart disease
Cardiovascular 316996 316996 0 0
Hypertension
Cardiovascular 316997 316997 0 0
Other cardiovascular diseases
Respiratory 317040 317040 0 0
Normal development and function of the respiratory system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This is a non-therapeutic mechanistic physiological study.

All of the following procedures will be conducted by the doctoral candidate under supervision of a trained human physiologist staff member. The laboratory where all assessments will take place is located at the Exercise Nutrition and Metabolism Laboratory, Department of Exercise Sciences, Newmarket Campus, University of Auckland.

All participants will undergo an initial visit to the laboratory where screening and familiarisation with all study protocol will take place. This visit will be 60 minutes duration, and an investigator will explain the nature of the study procedures, answer any questions, and obtain written informed consent from the participant. Anthropometric (height, weight), demographic, general health, physical activity readiness (Get Active questionnaire) and physical activity information will be obtained. Participants will then perform a handgrip strength test to enable classification of participants by strength (resistance training assessment) and a graded maximal exercise test to categorise participants according to their aerobic capacity (endurance training assessment).

During the handgrip strength test participants will use their dominant hand to maximally squeeze the dynamometer, with the highest of three trials obtained as the final value. During the graded maximal exercise test, participants will be instrumented with a heart rate monitor, mouthpiece and headset attached to a two-way valve with a room air inlet and outlet to a hose connected to a metabolic cart gas analysis system. Participants will perform 5-minute warm up at a self-selected pace, followed by a 3-minute adjustment period to determine the participant’s optimal speed for the duration of the maximal exercise test. The selected speed will remain constant for the duration of the test, with the gradient of the motorized treadmill increasing by 1% every 1 minute, beginning at 0%.

The second visit will be an experimental session. This visit will be scheduled ~2-7 days after the initial familiarisation/screening visit, as appropriate. However, premenopausal women will be studied during the first five days of their menstrual cycle (early follicular phase) or during the placebo/no-hormone phase of oral contraceptive use, as appropriate. This visit will be 90 minutes duration.

At the experimental session, participants will be asked to sit in a comfortable armchair and remain in that position throughout the session. Participants will be instrumented for continuous monitoring of blood pressure, heart rate, respiration and brain blood flow. More specifically, beat-to-beat blood pressure will be measured using finger photoplethysmography, using a small lightweight cuff wrapped around the finger and a cuff wrapped around the upper arm for calibration. Heart rate will be measured using standard electrocardiogram involving the placement of 3 sticky electrodes on the collarbones and chest (standard 3 lead ECG). Participants will wear a mouthpiece and nose clip to monitor respiration. Brain blood flow will be monitored using a transcranial Doppler ultrasound, with a probe placed over the temporal ‘window’ in front of the ear and above the zygomatic arch. The probe will be fixed in place using an adjustable headband and small amount of ultrasound gel.

After instrumentation, a 15 minute resting baseline will be observed with the last 5 minutes used for analysis, followed by chemoreflex assessment. Chemoreflex assessment will involve two breathing tests. Tests are separated by a 15 minute rest period. The first test is isocapnic hypoxia (10% O2-90% N2), used to evaluate peripheral chemoreflex stimulation. The exposure will last 5 minutes, with end tidal oxygen of ~45mmHg and end tidal carbon dioxide of ~40mmHg maintained throughout the test. The second test is hyperoxic hypercapnia (CO2 rebreathing), used to evaluate central chemoreflex stimulation with diminished peripheral chemoreflex stimulation). The participant will then be coached using a metronome and verbal feedback to hyperventilate in room air, until attaining an end tidal carbon dioxide concentration of ~25mmHg. Upon reaching this, the participant will be asked to perform a maximal expiration below functional residual capacity. Upon completion, the inspiratory source will be switched to a rebreathing bag filled with ~95% O2-~5% CO2, and the participant will be instructed to perform 5-6 deep and rapid breaths. Following this, the participant will be instructed to breath as required, until their end tidal carbon dioxide reaches ~55mmHg, signalling the end of the test.
Intervention code [1] 318580 0
Early detection / Screening
Comparator / control treatment
The participant group who are sedentary will be age and sex matched to act as a control against resistance or aerobically trained participants. Participants will all receive the same treatment, and will also act as their own controls versus baseline values.
Control group
Active

Outcomes
Primary outcome [1] 325106 0
Peripheral chemoreflex sensitivity (i.e., cardiorespiratory responses to isocapnic hypoxia).
Timepoint [1] 325106 0
Peripheral chemoreflex sensitivity will be assessed once, during the isocapnic hypoxia breathing test.
Secondary outcome [1] 386858 0
Central chemoreflex sensitivity (i.e., cardiorespiratory responses to hypercapnic hyperoxia)
Timepoint [1] 386858 0
Central chemoreflex sensitivity will be assessed once, during the CO2 rebreathing test.

Eligibility
Key inclusion criteria
• Aged 18-45 years old
• Men and women
• Healthy, with no chronic medical conditions (able to pass a PAR-Q+ questionnaire)
• Classified as either;

Endurance trained (participating in 4 or more hours per week of either type of training, on two or more days per week, for a continuous period of >12 months AND VO2peak >60 mL/kg/min for males or >55 mL/kg/min for females);

Resistance trained (participating in 4 or more hours per week of resistance training, on two or more days per week, for a continuous period of >12 months AND hand grip strength >58 kg for males or >38 kg for females);

Untrained (not engaging in any regular physical activity AND VO2max <41 mL/kg/min for males and <35 mL/kg/min females)
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
• BMI <18 kg/m2
• Current smoker
• Users of recreational drugs
• Abusers of alcohol
• Underlying medical conditions
• Current pregnancy

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Other
Other design features
All three groups (resistance trained, aerobic trained and untrained) will receive all interventions with isocapnic hypoxia performed first followed by CO2 rebreathing.
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Sample size estimates are based on Somers et al. who observed that minute ventilation increased by 96% (SD = 66) during isocapnic hypoxia (10% O2-90% N2 with titrated CO2). Therefore, with a sample size of 25 per group (75 in total) at 80% power and 5% alpha (two sample t-test) and assuming a similar standard deviation in all groups (resistance trained endurance trained and untrained), the minimal detectable difference would be 53% between any two groups in the minute ventilation response.

Anthropometric (e.g., BMI) and demographic (e.g., age) information gathered during the familiarisation/screening visit will be quantified using descriptive statistics (mean, SD, Median, IQR) and graphical presentations (boxplots, histograms, scatter plots). Normal distribution will be evaluated with Shapiro-Wilk tests. Levene’s test will be used to determine equal variance. A one-way repeated measures ANOVA will be used to compare the influence of exercise training history (resistance, endurance or untrained) on chemoreflex sensitivity. The Kruskal-Wallis test will be used for non-normally distributed data. Statistical analysis will be conducted using SPSS (IBM Corp.,). Significance will be set at p<0.05. Normally distributed data will be presented as mean (SD) while non-normally distributed data will be presented as median (interquartile range).

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
26/10/2020
Actual
27/10/2020
Date of last participant enrolment
Anticipated
30/04/2022
Actual
Date of last data collection
Anticipated
31/05/2022
Actual
Sample size
Target
75
Accrual to date
33
Final
Recruitment outside Australia
Country [1] 22985 0
New Zealand
State/province [1] 22985 0
Auckland

Funding & Sponsors
Funding source category [1] 306719 0
University
Name [1] 306719 0
University of Auckland
Country [1] 306719 0
New Zealand
Primary sponsor type
University
Name
University of Auckland
Address
Faculty of Medical and Health Sciences
85 Park Road
Grafton
Auckland 1023
New Zealand
Country
New Zealand
Secondary sponsor category [1] 307302 0
None
Name [1] 307302 0
Address [1] 307302 0
Country [1] 307302 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 306889 0
Central Health and Disability Ethics Committee
Ethics committee address [1] 306889 0
Ethics committee country [1] 306889 0
New Zealand
Date submitted for ethics approval [1] 306889 0
05/08/2020
Approval date [1] 306889 0
25/08/2020
Ethics approval number [1] 306889 0
20/CEN/176

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 105358 0
Miss Thalia Babbage
Address 105358 0
Faculty of Medical and Health Sciences Department of Physiology
University of Auckland
85 Park Road
Grafton Auckland 1023
Country 105358 0
New Zealand
Phone 105358 0
+64 277468230
Fax 105358 0
Email 105358 0
[email protected]
Contact person for public queries
Name 105359 0
Thalia Babbage
Address 105359 0
Faculty of Medical and Health Sciences Department of Physiology
University of Auckland
85 Park Road
Grafton Auckland 1023
Country 105359 0
New Zealand
Phone 105359 0
+64 277468230
Fax 105359 0
Email 105359 0
[email protected]
Contact person for scientific queries
Name 105360 0
Thalia Babbage
Address 105360 0
Faculty of Medical and Health Sciences Department of Physiology
University of Auckland
85 Park Road
Grafton Auckland 1023
Country 105360 0
New Zealand
Phone 105360 0
+64 277468230
Fax 105360 0
Email 105360 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.